This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JDE-001

EyeGate Pharmaceuticals, Inc.

Drug Names(s): thiolated HA topical drop (0.4%)

Description: JDE-001 is a topical drop containing cross-linked thiolated hyaluronic acid (HA) at a concentration of 0.4%. HA is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints and functions as a cushion and lubricant.

Low-concentration, non-cross-linked HA-based eye drops are a global standard of care for a variety of underlying indications, including dry eye disease and contact lens wetting. Cross-linked thiolated HA breaks down in the body to release HA and may extend HA residency. An identical formulation to JDE-001 already exists as a veterinary product sold by BayerDVM worldwide under the Remend brand to treat dry eye disease. Head-to-head animal studies have demonstrated the superiority of this cross-linked HA formulation over currently marketed, non-cross-linked products.

Cross-linked thiolated HA at a higher concentration is being developed under the drug name JDE-003.

As JDE-001 is regulated as a drug in the U.S., all information pertaining to U.S. development will be found in this BioMedTracker profile. As JDE-001 is regulated as a device in Europe, all information pertaining to the European development will be found in the JDE-001 MedDeviceTracker profile.

Deal Structure: BioTime and Jade Therapeutics
In September 2013, BioTime announced the signing of an exclusive sublicense agreement with Jade Therapeutics. This new agreement supersedes previous sublicense and supply agreements and expands the licensed Field of Use to include certain additional uses, such as the use of BioTimes HyStem hydrogel technology for the delivery of all potential therapeutic molecules to the human eye. Excluded from the licensed Field of Use is the use of the HyStem technology for the delivery of cells with or without any molecules necessary for the therapeutic benefit of those cells, for use in making punctal plugs, for diagnostic and research reagents, and for non-human applications. Jades lead products in pre-clinical development utilize the licensed hydrogel technology to facilitate time-release, topical delivery of recombinant human growth hormone to help heal lesions on the ocular surface, as well as enable local delivery of antibiotics to treat ocular...See full deal structure in Biomedtracker

Partners: BioTime, Inc.


JDE-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug